Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial - Poll - MDSpire

Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial

  • By

  • Filip Ventorp

  • Marie Asp

  • Sofia Olsson

  • Jesper Lindahl

  • Stefan Möller

  • Martina Svensson

  • Filip Ängeby

  • Armida Pravdinske

  • Johanna Tjernberg

  • Susann Schrey

  • Darya Ståhl

  • Viktor Magnusson

  • Emilia Eliasson

  • Anna Agelii-Weber

  • Erika Stålhammar

  • Danielle van Westen

  • Tomas Deierborg

  • Kristoffer N. T. Månsson

  • Diego A. Pizzagalli

  • Åsa Hammar

  • Åsa B. Tornberg

  • Johannes Björkstrand

  • Daniel Lindqvist

  • June 12, 2026

  • 0 min

Share

Original Source(s)

Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial

  • by Filip Ventorp, Marie Asp, Sofia Olsson, Jesper Lindahl, Stefan Möller, Martina Svensson, Filip Ängeby, Armida Pravdinske, Johanna Tjernberg, Susann Schrey, Darya Ståhl, Viktor Magnusson, Emilia Eliasson, Anna Agelii-Weber, Erika Stålhammar, Danielle van Westen, Tomas Deierborg, Kristoffer N. T. Månsson, Diego A. Pizzagalli, Åsa Hammar, Åsa B. Tornberg, Johannes Björkstrand, Daniel Lindqvist

  • June 12, 2026

Related Content

Personalized vs. population-based speech models for multi-dimensional mental health prediction

Beyond aesthetic outcomes: psychodermatological benefits of botulinum toxin treatment in the upper facial third. A narrative review

Comparative effects of structured exercise protocols on depression and anxiety symptoms: a network meta-analysis